Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending:	O
___.	O
Chief	O
Complaint:	O
CC:	O
___	O
Reason	O
for	O
OSH	O
transfer:	O
pancreatitis	O
and	O
choledocholithiasis	O
with	O
obstruction	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
none	O
History	O
of	O
Present	O
Illness:	O
Mr	O
___	O
is	O
a	O
___	O
with	O
heavy	O
smoking,	O
AAA	O
s/p	O
endovascular	O
repair	O
___,	O
HTN,	O
HCV	O
cirrhosis	O
with	O
esophageal	B-Upper_gastrointestinal_haemorrhage
varices	B-Upper_gastrointestinal_haemorrhage
(never	I-Upper_gastrointestinal_haemorrhage
bled,	B-Upper_gastrointestinal_haemorrhage
never	O
banded),	O
who	O
presents	O
from	O
___	O
with	O
pancreatitis	O
and	O
CT	O
scan	O
reportedly	O
showing	O
choledocholithiasis	O
(CBD	O
stone).	O
He	O
felt	O
well	O
until	O
the	O
___	O
afternoon	O
prior	O
to	O
presentation,	O
when	O
he	O
ate	O
a	O
peanut	O
butter	O
and	O
jelly	O
sandwich	O
and	O
became	O
nauseated.	O
It	O
continued	O
over	O
the	O
course	O
of	O
the	O
day,	O
getting	O
progressively	O
worse.	O
On	O
___,	O
he	O
started	O
to	O
develop	O
epigastric	O
and	O
bandlike	O
abdominal	O
pain,	O
which	O
was	O
also	O
described	O
as	O
gassy	O
in	O
character.	O
This	O
worsened	O
over	O
the	O
course	O
of	O
the	O
day,	O
and	O
brought	O
him	O
into	O
___.	O
At	O
___,	O
he	O
was	O
reportedly	O
stable.	O
Labs	O
showed	O
pancreatitis,	O
elevated	O
LFTs,	O
and	O
CT	O
scan	O
of	O
the	O
abdomen	O
showed	O
pancreatic	O
head	O
and	O
duodenal	O
stranding	O
and	O
CBD	O
stone,	O
by	O
report.	O
He	O
was	O
given	O
Unasyn	O
there,	O
for	O
unclear	O
reasons.	O
He	O
was	O
then	O
transferred	O
to	O
the	O
___.	O
In	O
the	O
___	O
ED,	O
he	O
had	O
stable	O
vital	O
signs,	O
and	O
repeat	O
labs	O
confirmed	O
transaminitis,	O
hyperbilirubinemia,	O
and	O
pancreatitis.	O
He	O
was	O
given	O
Zosyn	O
and	O
then	O
admission	O
was	O
requested.	O
Upon	O
arrival,	O
his	O
Plts	O
are	O
noted	O
to	O
be	O
12,	O
and	O
review	O
of	O
his	O
records	O
calls	O
into	O
question	O
the	O
finding	O
of	O
CBD	O
stone	O
--	O
not	O
mentioned	O
on	O
CT	O
scan	O
read,	O
and	O
ERCP	O
team	O
cannot	O
find	O
it.	O
I	O
spoke	O
with	O
radiology	O
and	O
they	O
confirm	O
that	O
they	O
do	O
not	O
see	O
a	O
stone	O
on	O
this	O
study,	O
but	O
there	O
is	O
some	O
intrahepatic	O
ductal	O
dilatation.	O
Recommended	O
MRCP	O
and	O
dynamic	O
liver	O
for	O
further	O
eval.	O
ROS:	O
A	O
complete	O
10-point	O
ROS	O
was	O
completed	O
and	O
is	O
otherwise	O
negative	O
in	O
detail	O
except	O
per	O
HPI.	O
Past	O
Medical	O
History:	O
HCV	O
cirrhosis	O
-	O
previously	O
attempted	O
old	O
generation	O
treatment,	O
no	O
recent	O
VL	O
on	O
file	O
Esophageal	O
varices	O
-	O
reportedly	O
stable	O
for	O
years,	O
last	O
endoscopy	O
was	O
___	O
year	O
ago;	O
___	O
EGD	O
in	O
OMR	O
showed	O
grade	O
3	O
varices	O
HTN	O
Seasonal	O
allergies	O
Surgical	O
history:	O
AAA	O
endovascular	O
repair	O
(Drs	O
___	O
at	O
___,	O
___	O
Stabbing	O
resulting	O
in	O
Ex-lap,	O
___	O
Social	O
History:	O
___	O
Family	O
History:	O
He	O
was	O
adopted.	O
Physical	O
Exam:	O
ON	O
ADMISSION:	O
Vitals:	O
AF/97.9,	O
90s-100s/50s-60s,	O
60s-70s,	O
___,	O
94%RA	O
Gen:	O
NAD,	O
lying	O
in	O
bed	O
Eyes:	O
EOMI,	O
sclerae	O
anicteric	O
ENT:	O
MMM,	O
OP	O
clear	O
Cardiovasc:	O
RRR,	O
no	O
MRG,	O
full	O
pulses,	O
trace	O
edema	O
Resp:	O
normal	O
effort,	O
no	O
accessory	O
muscle	O
use,	O
lungs	O
CTA	O
___.	O
GI:	O
soft,	O
tender	O
across	O
epigastrum,	O
mildly	O
distended	O
(adipose),	O
BS+	O
MSK:	O
No	O
significant	O
kyphosis.	O
No	O
palpable	O
synovitis.	O
Skin:	O
No	O
visible	O
rash.	O
Jaundiced.	O
Neuro:	O
AAOx3.	B-Delirium
No	O
facial	O
droop.	O
Psych:	O
Full	O
range	O
of	O
affect.	O
Very	O
pleasant.	O
GU:	O
No	O
foley.	O
ON	O
DISCHARGE:	O
Patient	O
deceased.	O
Pertinent	O
Results:	O
ON	O
ADMISSION	O
___	O
07:59AM	O
LACTATE-1.3	O
___	O
07:53AM	O
GLUCOSE-109*	O
UREA	O
N-24*	O
CREAT-0.8	O
SODIUM-137	O
POTASSIUM-4.4	O
CHLORIDE-99	O
TOTAL	O
CO2-30	O
ANION	O
GAP-12	O
___	O
07:53AM	O
ALT(SGPT)-85*	O
AST(SGOT)-167*	O
ALK	O
PHOS-59	O
TOT	O
BILI-5.8*	O
___	O
07:53AM	O
LIPASE-449*	O
___	O
07:53AM	O
ALBUMIN-3.2*	O
CALCIUM-8.6	O
PHOSPHATE-3.8	O
MAGNESIUM-1.7	O
___	O
07:53AM	O
WBC-7.8#	O
RBC-3.68*	O
HGB-13.0*	O
HCT-37.9*	O
MCV-103*#	O
MCH-35.4*	O
MCHC-34.3	O
RDW-16.9*	O
___	O
07:53AM	O
PLT	O
COUNT-12*#	O
___	O
07:53AM	O
___	O
PTT-29.8	O
___	O
ON	O
DISCHARGE	O
(patient	O
deceased)	O
___	O
07:35AM	O
BLOOD	O
WBC-7.3	O
RBC-2.61*	O
Hgb-10.6*	O
Hct-32.8*	O
MCV-126*	O
MCH-40.4*	O
MCHC-32.2	O
RDW-21.2*	O
Plt	O
Ct-13*#	O
___	O
07:35AM	O
BLOOD	O
Plt	O
Ct-13*#	O
___	O
07:35AM	O
BLOOD	O
___	O
PTT-29.0	O
___	O
___	O
07:35AM	O
BLOOD	O
___	O
___	O
07:35AM	O
BLOOD	O
Glucose-107*	O
UreaN-49*	O
Creat-1.4*	O
Na-136	O
K-3.8	O
Cl-99	O
HCO3-29	O
AnGap-12	O
___	O
07:35AM	O
BLOOD	O
ALT-48*	O
AST-92*	O
AlkPhos-64	O
TotBili-3.5*	O
___	O
07:35AM	O
BLOOD	O
Calcium-9.2	O
Phos-4.2	O
Mg-2.1	O
MICRO	O
___	O
10:30	O
pm	O
SPUTUM	O
Source:	O
Induced.	O
GRAM	O
STAIN	O
(Final	O
___:	O
___	O
PMNs	O
and	O
>10	O
epithelial	O
cells/100X	O
field.	O
Gram	O
stain	O
indicates	O
extensive	O
contamination	O
with	O
upper	O
respiratory	O
secretions.	O
Bacterial	O
culture	O
results	O
are	O
invalid.	O
PLEASE	O
SUBMIT	O
ANOTHER	O
SPECIMEN.	O
RESPIRATORY	O
CULTURE	O
(Final	O
___:	O
TEST	O
CANCELLED,	O
PATIENT	O
CREDITED.	O
Immunoflourescent	O
test	O
for	O
Pneumocystis	O
jirovecii	O
(carinii)	O
(Final	O
___:	O
Reported	O
to	O
and	O
read	O
back	O
by	O
___	O
___	O
@___,	O
___.	O
SPECIMEN	O
NOT	O
PROCESSED	O
DUE	O
TO:	O
QUANTITY	O
NOT	O
SUFFICIENT.	O
Less	O
than	O
2	O
ml	O
received.	O
PLEASE	O
SUBMIT	O
ANOTHER	O
SPECIMEN.	O
TEST	O
CANCELLED,	O
PATIENT	O
CREDITED.	O
FUNGAL	O
CULTURE	O
(Preliminary):	O
ACID	O
FAST	O
SMEAR	O
(Final	O
___:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
CONCENTRATED	O
SMEAR.	O
ACID	O
FAST	O
CULTURE	O
(Preliminary):	O
___	O
2:10	O
pm	O
SPUTUM	O
Source:	O
Expectorated.	O
GRAM	O
STAIN	O
(Final	O
___:	O
___	O
PMNs	O
and	O
>10	O
epithelial	O
cells/100X	O
field.	O
Gram	O
stain	O
indicates	O
extensive	O
contamination	O
with	O
upper	O
respiratory	O
secretions.	O
Bacterial	O
culture	O
results	O
are	O
invalid.	O
PLEASE	O
SUBMIT	O
ANOTHER	O
SPECIMEN.	O
RESPIRATORY	O
CULTURE	O
(Final	O
___:	O
TEST	O
CANCELLED,	O
PATIENT	O
CREDITED.	O
FUNGAL	O
CULTURE	O
(Preliminary):	O
___	O
12:10	O
pm	O
URINE	O
Source:	O
___.	O
**FINAL	O
REPORT	O
___	O
URINE	O
CULTURE	O
(Final	O
___:	O
<10,000	O
organisms/ml.	O
___	O
4:35	O
pm	O
SPUTUM	O
Source:	O
Expectorated.	O
**FINAL	O
REPORT	O
___	O
GRAM	O
STAIN	O
(Final	O
___:	O
___	O
PMNs	O
and	O
>10	O
epithelial	O
cells/100X	O
field.	O
Gram	O
stain	O
indicates	O
extensive	O
contamination	O
with	O
upper	O
respiratory	O
secretions.	O
Bacterial	O
culture	O
results	O
are	O
invalid.	O
PLEASE	O
SUBMIT	O
ANOTHER	O
SPECIMEN.	O
RESPIRATORY	O
CULTURE	O
(Final	O
___:	O
TEST	O
CANCELLED,	O
PATIENT	O
CREDITED.	O
___	O
7:29	O
am	O
BLOOD	O
CULTURE	O
#2.	O
**FINAL	O
REPORT	O
___	O
Blood	O
Culture,	O
Routine	O
(Final	O
___:	O
NO	O
GROWTH.	O
___	O
9:00	O
pm	O
IMMUNOLOGY	O
**FINAL	O
REPORT	O
___	O
HCV	O
VIRAL	O
LOAD	O
(Final	O
___:	O
1,580,000	O
IU/mL.	O
Performed	O
using	O
Cobas	O
Ampliprep	O
/	O
Cobas	O
Taqman	O
HCV	O
v2.0	O
Test.	O
Linear	O
range	O
of	O
quantification:	O
1.50E+01	O
IU/mL	O
-	O
1.00E+08	O
IU/mL.	O
Limit	O
of	O
detection:	O
1.50E+01	O
IU/mL.	O
___	O
9:00	O
pm	O
IMMUNOLOGY	O
**FINAL	O
REPORT	O
___	O
HBV	O
Viral	O
Load	O
(Final	O
___:	O
HBV	O
DNA	O
not	O
detected.	O
Performed	O
using	O
the	O
Cobas	O
Ampliprep	O
/	O
Cobas	O
Taqman	O
HBV	O
Test	O
v2.0.	O
Linear	O
range	O
of	O
quantification:	O
20	O
IU/mL	O
-	O
170	O
million	O
IU/mL.	O
Limit	O
of	O
detection:	O
20	O
IU/mL.	O
___	O
7:45	O
am	O
BLOOD	O
CULTURE	O
SET#2.	O
**FINAL	O
REPORT	O
___	O
Blood	O
Culture,	O
Routine	O
(Final	O
___:	O
NO	O
GROWTH.	O
IMAGING	O
Chest	O
portable	O
___:	O
The	O
patient	O
has	O
severe	O
emphysema.	O
New	O
heterogeneous	O
opacification	O
confined	O
to	O
the	O
right	O
lower	O
lobe	O
is	O
pneumonia	B-Lower_respiratory_tract_infection
or	O
pulmonary	O
hemorrhage	O
or	O
both.	O
There	O
is	O
no	O
pulmonary	O
edema.	O
Pleural	O
effusion	O
is	O
small	O
if	O
any.	O
No	O
pneumothorax.	O
Heart	O
size	O
normal.	O
Bulging	O
contour	O
to	O
the	O
left	O
diaphragmatic	O
pleural	O
surface	O
it	O
is	O
due	O
to	O
a	O
documented	O
Bochdalek's	O
diaphragmatic	O
hernia	O
transmitting	O
subphrenic	O
fat.	O
ECG	O
___:	O
Normal	O
sinus	O
rhythm.	O
Suspect	O
acute	O
myocardial	O
infarction	O
anterolaterally	O
with	O
marked	O
increase	O
in	O
ST-T	O
wave	O
abnormalities	O
in	O
comparison	O
to	O
tracing	O
#1.	O
TRACING	O
#2	O
ECG	O
___:	O
Normal	O
sinus	O
rhythm.	O
Anteroseptal	O
myocardial	O
infarction	O
of	O
indeterminate	O
age.	O
Diffuse	O
ST-T	O
wave	O
abnormalities.	O
Consider	O
acute	O
myocardial	O
infarction.	O
The	O
Q-T	O
interval	O
is	O
borderline	O
prolonged.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
the	O
T	O
wave	O
abnormalities	O
are	O
less	O
marked.	O
Marked	O
left	O
axis	O
deviation	O
persists	O
as	O
does	O
evidence	O
of	O
recent	O
anteroseptal	O
myocardial	O
infarction.	O
TRACING	O
#1	O
Chest	O
pa/lat	O
___:	O
Heart	O
size	O
is	O
mildly	O
enlarged,	O
stable.	O
Mediastinal	O
contours	O
are	O
stable.	O
Lungs	O
are	O
essentially	O
clear.	O
There	O
is	O
no	O
appreciable	O
pleural	O
effusion	O
or	O
pneumothorax.	O
No	O
new	O
focal	O
consolidations	O
to	O
suggest	O
interval	O
development	O
of	O
infection	O
demonstrated	O
ECG	O
___:	O
Sinus	O
rhythm	O
with	O
a	O
slightly	O
prolonged	O
computed	O
QTc	O
interval.	O
QS	O
complexes	O
in	O
leads	O
V1-V2	O
with	O
poor	O
anterior	O
R	O
wave	O
progression	O
in	O
lead	O
V3	O
with	O
T	O
wave	O
inversions	O
in	O
leads	O
I,	O
aVL,	O
and	O
V2-V6	O
suggest	O
recent	O
anterolateral	O
myocardial	O
infarction	O
in	O
evolution.	O
There	O
is	O
left	O
axis	O
deviation	O
and	O
left	O
anterior	O
fascicular	O
block.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
ST	O
segment	O
elevation	O
is	O
less	O
prominent	O
in	O
lead	O
V2	O
but	O
slightly	O
more	O
prominent	O
in	O
lead	O
V1	O
suggesting	O
recent	O
injury	O
or	O
post	O
infarction	O
aneurysm	O
formation.	O
QTc	O
interval	O
remains	O
prolonged.	O
Alternatively,	O
an	O
ongoing	O
anterolateral	O
ischemic	O
process	O
cannot	O
be	O
excluded.	O
Clinical	O
correlation	O
is	O
suggested.	O
ECG	O
___:	O
Baseline	O
artifact.	O
Probable	O
sinus	O
rhythm.	O
Left	O
axis	O
deviation.	O
Consider	O
left	O
anterior	O
fascicular	O
block.	O
QTc	O
interval	O
prolongation.	O
Q	O
waves	O
in	O
leads	O
V1-V2	O
and	O
late	O
R	O
wave	O
progression	O
with	O
early	O
precordial	O
ST	O
segment	O
elevation	O
and	O
T	O
wave	O
inversion.	O
Possible	O
anterolateral	O
myocardial	O
infarction	O
or	O
metabolic	O
derangements.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
the	O
QTc	O
interval	O
is	O
longer	O
at	O
a	O
slower	O
rate	O
and	O
T	O
wave	O
inversions	O
are	O
new	O
in	O
the	O
precordial	O
leads.	O
Clinical	O
correlation	O
is	O
suggested.	O
Chest	O
portable	O
___:	O
As	O
compared	O
to	O
___	O
radiograph,	O
a	O
right	O
lower	O
lobe	O
consolidation	O
and	O
focal	O
left	O
basilar	O
atelectasis	O
have	O
resolved.	O
Cardiomediastinal	O
contours	O
are	O
stable.	O
There	O
is	O
no	O
evidence	O
of	O
pulmonary	O
edema.	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Left	O
axis	O
deviation.	O
There	O
are	O
Q	O
waves	O
in	O
the	O
anterior	O
leads	O
with	O
ST	O
segment	O
elevation	O
and	O
additional	O
ST-T	O
wave	O
changes	O
consistent	O
with	O
ischemia	O
or	O
infarction.	O
Clinical	O
correlation	O
is	O
suggested.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
ST	O
segment	O
elevation	O
and	O
ST-T	O
wave	O
changes	O
are	O
much	O
more	O
significant.	O
Tissue:	O
BONE	O
MARROW,	O
BIOPSY,	O
CORE	O
___	O
NOTE:	O
Erythroid	O
dominant	O
bone	O
marrow	O
aspirate	O
with	O
maturing	O
trilineage	O
hematopoiesis.	O
While	O
no	O
overt	O
myeloid	O
dysplasia	O
seen,	O
the	O
core	O
biopsy	O
is	O
nondiagnostic	O
because	O
is	O
lacks	O
hematopoietic	O
cellular	O
elements.	O
Chest	O
pa/lat	O
___:	O
1.	O
Near	O
resolution	O
of	O
pulmonary	O
edema.	O
2.	O
New	O
right	O
lower	O
lobe	O
airspace	O
opacity,	O
which	O
may	O
reflect	O
aspiration	O
or	O
developing	O
infectious	O
pneumonia	B-Lower_respiratory_tract_infection
here	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Left	O
anterior	O
fascicular	O
block.	O
Non-specific	O
ST	O
segment	O
changes.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
the	O
suggestion	O
of	O
a	O
possible	O
prior	O
anteroseptal	O
myocardial	O
infarction	O
is	O
less	O
pronounced.	O
Lateral	O
ST	O
segment	O
depressions	O
persist.	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Leftward	O
axis.	O
Anterior	O
myocardial	O
infarction,	O
age	O
indeterminate.	O
Non-specific	O
lateral	O
ST-T	O
wave	O
changes.	O
Cannot	O
rule	O
out	O
myocardial	O
ischemia.	O
Clinical	O
correlation	O
is	O
suggested.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
the	O
lateral	O
ST	O
segment	O
depressions	O
are	O
slightly	O
more	O
apparent.	O
CXR	O
___:	O
As	O
compared	O
to	O
the	O
previous	O
radiograph,	O
the	O
severity	O
of	O
the	O
pre-existing	O
pulmonary	O
edema	O
has	O
increased.	O
The	O
patient	O
is	O
now	O
in	O
moderate	O
pulmonary	O
edema.	O
With	O
mild	O
interstitial	O
components.	O
Moderate	O
cardiomegaly.	O
Mild	O
elongation	O
of	O
the	O
descending	O
aorta.	O
No	O
larger	O
pleural	O
effusions.	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Left	O
axis	O
deviation.	O
Probable	O
prior	O
anteroseptal	O
myocardial	O
infarction.	O
Non-specific	O
inferolateral	O
ST-T	O
wave	O
abnormalities.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
the	O
ST	O
segment	O
depression	O
is	O
less	O
pronounced	O
in	O
lead	O
V6	O
and	O
the	O
QRS	O
change	O
in	O
lead	O
V4	O
could	O
be	O
due	O
to	O
lead	O
placement.	O
ECHO	O
___:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
septal,	O
anterior	O
and	O
apical	O
hypokinesis.	O
The	O
other	O
segments	O
are	O
relatively	O
hyperdynamic.	O
Doppler	O
parameters	O
are	O
indeterminate	O
for	O
left	O
ventricular	O
diastolic	O
function.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal.	O
with	O
focal	O
hypokinesis	O
of	O
the	O
apical	O
free	O
wall.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis.	O
No	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Mild	O
(1+)	O
mitral	O
regurgitation	O
is	O
seen.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
IMPRESSION:	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
as	O
described	O
above	O
and	O
apical	O
righ	O
ventricular	O
hypokinesis	O
consistent	O
with	O
mid-LAD	O
ischemia.	O
Mild	O
mitral	O
regurgitation.	O
Compared	O
with	O
the	O
prior	O
study	O
(images	O
reviewed)	O
of	O
___,	O
image	O
quali	O
is	O
improved	O
on	O
the	O
current	O
study.	O
The	O
anterior/septal	O
segments	O
were	O
probably	O
hypokinetic	O
on	O
the	O
prior	O
study	O
also.	O
Estimated	O
pulmonary	O
pressures	O
are	O
higher.	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Leftward	O
axis.	O
Q	O
waves	O
in	O
leads	O
V1-V2	O
with	O
ST	O
segment	O
elevation	O
through	O
lead	O
V3.	O
Consider	O
anteroseptal	O
myocardial	O
infarction	O
of	O
indeterminate	O
age.	O
Lateral	O
and	O
inferior	O
ST-T	O
wave	O
abnormalities.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
Q	O
waves	O
and	O
ST	O
segment	O
elevation	O
in	O
the	O
early	O
precordial	O
leads	O
are	O
now	O
more	O
apparent.	O
ST	O
segment	O
depressions	O
in	O
the	O
lateral	O
leads	O
are	O
also	O
more	O
prominent.	O
Clinical	O
correlation	O
is	O
suggested.	O
___	O
___:	O
No	O
evidence	O
of	O
deep	O
venous	O
thrombosis	O
in	O
the	O
bilateral	O
lower	O
extremity	O
veins.	O
CTA	O
chest	O
___:	O
1.	O
No	O
evidence	O
of	O
pulmonary	O
embolism	O
or	O
aortic	O
abnormality.	O
Atherosclerotic	O
plaque	O
of	O
the	O
aorta	O
and	O
coronary	O
arteries.	O
2.	O
Diffuse	O
peribronchial/bronchial	O
wall	O
thickening	O
compatible	O
with	O
bronchitis,	B-Lower_respiratory_tract_infection
however,	O
in	O
combination	O
with	O
mediastinal	O
and	O
hilar	O
lymphadenopathy,	O
and	O
further	O
evaluation	O
with	O
repeat	O
chest	O
CT	O
after	O
resolution	O
of	O
current	O
symptoms	O
is	O
recommended	O
to	O
ensure	O
resolution	O
of	O
these	O
findings.	O
3.	O
Paraseptal	O
emphysema.	O
Small	O
bilateral	O
pleural	O
effusions	O
and	O
interlobular	O
septal	O
thickening	O
compatible	O
with	O
pulmonary	O
vascular	O
congestion.	O
4.	O
Findings	O
consistent	O
with	O
hepatic	O
cirrhosis	O
and	O
portal	O
hypertension	O
including	O
splenomegaly	O
and	O
varices.	O
Mild	O
bilateral	O
renal	O
lesions,	O
including	O
2	O
cysts	O
in	O
the	O
right	O
upper	O
pole	O
and	O
a	O
left	O
upper	O
pole	O
hypodensity	O
too	O
small	O
to	O
characterize.	O
Chest	O
portable	O
___:	O
1.	O
Mild	O
pulmonary	O
edema.	O
2.	O
Tiny	O
right	O
effusion.	O
ECHO	O
___:	O
The	O
left	O
atrium	O
is	O
elongated.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal.	O
Due	O
to	O
suboptimal	O
technical	O
quality,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
cannot	O
be	O
fully	O
excluded.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(LVEF>55%).	O
There	O
is	O
no	O
ventricular	O
septal	O
defect.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal.	O
The	O
diameters	O
of	O
aorta	O
at	O
the	O
sinus,	O
ascending	O
and	O
arch	O
levels	O
are	O
normal.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis.	O
No	O
aortic	O
regurgitation	O
is	O
seen.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
ECG	O
___:	O
Sinus	O
rhythm.	O
Delayed	O
R	O
wave	O
transition.	O
Non-specific	O
ST	O
segment	O
changes.	O
No	O
previous	O
tracing	O
available	O
for	O
comparison.	O
MRCP	O
___:	O
Cirrhosis	O
with	O
sequela	O
of	O
portal	O
hypertension.	O
Multifocal,	O
patchy	O
areas	O
of	O
abnormal	O
signal	O
and	O
enhancement,	O
most	O
suggestive	O
of	O
inflammatory	O
fibrosis.	O
Given	O
associated	O
dilated	O
segment	O
4A/8	O
peripheral	O
ducts,	O
subclinical	O
cholangitis	O
should	O
be	O
considered.	O
Given	O
lack	O
of	O
washout,	O
tumor	O
is	O
thought	O
to	O
be	O
less	O
likely.	O
However,	O
as	O
this	O
is	O
not	O
entirely	O
excluded,	O
correlation	O
with	O
AFP	O
and	O
consideration	O
of	O
biopsy	O
and/or	O
short	O
term	O
(3	O
months)	O
MRI	O
follow	O
up	O
is	O
recommended.	O
CXR	O
___:	O
1.	O
Nodular	O
opacities	O
within	O
right	O
upper	O
lobe	O
may	O
represent	O
mucous	O
plugging	O
and	O
small	O
airways	O
disease.	O
2.	O
8	O
mm	O
rounded	O
opacification	O
the	O
left	O
lobe	O
lung	O
may	O
reflect	O
a	O
nipple	O
shadow.	O
Followup	O
chest	O
radiographs	O
with	O
and	O
without	O
nipple	O
markers	O
in	O
8	O
weeks	O
is	O
recommended.	O
Brief	O
Hospital	O
Course:	O
Hospital	O
course:	O
Mr.	O
___	O
is	O
a	O
___	O
y	O
M	O
with	O
PMH	O
significant	O
for	O
recent	O
AAA	O
repair,	O
HTN,	O
and	O
HCV	O
cirrhosis	O
who	O
transferred	O
from	O
OSH	O
for	O
evaluation	O
and	O
management	O
of	O
pancreatitis,	O
whose	O
course	O
was	O
complicated	O
by	O
acute	O
on	O
chronic	O
thombocytopenia,	O
with	O
contributions	O
from	O
hypersplenism	O
and	O
ITP,	O
requiring	O
IVIG	O
transfusions,	O
steroids,	O
and	O
rituxan.	O
His	O
hospital	O
course	O
was	O
further	O
complicated	O
by	O
NSTEMI,	O
associated	O
temporally	O
with	O
the	O
aforementioned	O
infusions,	O
with	O
management	O
of	O
ACS	O
limited	O
by	O
thrombocytopenia.	O
He	O
died	O
on	O
___	O
after	O
experiencing	O
torsades	O
and	O
ventricular	O
fibrillation,	O
despite	O
efforts	O
to	O
resuscitate	O
him.	O
Active	O
issues:	O
#Torsades/VF:	O
On	O
___,	O
he	O
was	O
noted	O
to	O
be	O
in	O
VF	O
and	O
a	O
code	O
was	O
called.	O
He	O
died	O
despite	O
efforts	O
to	O
resuscitate	O
him.	O
Review	O
of	O
telemetry	O
was	O
notable	O
for	O
torsades	O
followed	O
by	O
VF.	O
He	O
had	O
been	O
on	O
low	O
doses	O
of	O
trazodone,	O
which	O
had	O
been	O
discontinued	O
in	O
the	O
preceding	O
days,	O
as	O
he	O
was	O
noted	O
to	O
have	O
QT	O
prolongation.	O
The	O
etiology	O
may	O
have	O
been	O
myocardial	O
ischemia,	O
given	O
post-NSTEMI	O
state.	O
#	O
Thrombocytopenia:	O
While	O
he	O
had	O
chronically	O
low	O
platelets	O
due	O
to	O
his	O
cirrhosis	O
(50-80s	O
over	O
the	O
last	O
___	O
years),	O
his	O
platelet	O
count	O
dropped	O
dramatically	O
to	O
the	O
teens	O
during	O
this	O
admission,	O
which	O
was	O
attributed	O
to	O
ITP	O
and	O
splenic	O
sequestration.	O
Consumptive,	O
productive,	O
and	O
sequestrative	O
processes	O
were	O
considered.	O
BM	O
biopsy	O
was	O
reassuring	O
against	O
infiltrative	O
process	O
and	O
showed	O
maturing	O
trilineage	O
hematopoiesis.	O
Blood	O
smear	O
showed	O
anisocytosis	O
with	O
hypochromic	O
erythrocytes,	O
increased	O
numbers	O
of	O
reticulocytes,	O
normal	O
numbers	O
of	O
leukocytes,	O
hypersegmented	O
polymorphonuclear	O
cells,	O
decreased	O
numbers	O
of	O
platelets	O
with	O
normal	O
platelet	O
morphology;	O
therefore,	O
thrombotic	O
thrombocytopenic	O
purpura	O
was	O
not	O
likely.	O
His	O
fibrinogen	O
was	O
low,	O
consistent	O
with	O
coagulopathy	O
secondary	O
to	O
liver	O
disease.	O
He	O
was	O
treated	O
with	O
3	O
doses	O
IVIG,	O
steroids,	O
and	O
rituximab	O
given	O
in	O
MICU,	O
in	O
an	O
attempt	O
to	O
treat	O
ITP.	O
Splenic	O
embolization	O
was	O
considered	O
as	O
well,	O
however,	O
he	O
was	O
not	O
thought	O
to	O
be	O
stable	O
enough	O
to	O
withstand	O
the	O
procedure.	O
His	O
infusion	O
course	O
was	O
complicated	O
--	O
Rituximab	O
administration	O
on	O
___	O
was	O
complicated	O
by	O
chest	O
pain.	O
He	O
also	O
received	O
10	O
units	O
of	O
cryoprecipitate	O
on	O
___	O
for	O
dropping	O
fibrinogen.	O
In	O
addition,	O
on	O
___,	O
he	O
completed	O
a	O
4-day	O
pulse	O
dexamethasone	O
(40mg/day)	O
course,	O
unfortunately	O
with	O
suboptimal	O
response.	O
Platelet	O
transfusions	O
were	O
given	O
with	O
a	O
goal	O
platelet	O
count	O
>10,	O
with	O
concurrent	O
diuresis	O
after	O
IVIG	O
and	O
platelet	O
transfusions	O
were	O
temporally	O
associated	O
with	O
NSTEMI	O
thought	O
to	O
be	O
due	O
to	O
increased	O
myocardial	O
demand	O
in	O
the	O
setting	O
of	O
volume	O
load	O
(see	O
below	O
for	O
details	O
re:	O
ACS).	O
The	O
persistence	O
and	O
degree	O
of	O
thrombocytopenia	O
precluded	O
aggressive	O
treatment	O
of	O
acute	O
coronary	O
syndrome.	O
#	O
Hemoptysis:	O
Mr.	O
___	O
began	O
having	O
hemoptysis	O
___,	O
with	O
small	O
amounts	O
of	O
bloody	O
sputum	O
and	O
cough.	O
In	O
the	O
setting	O
of	O
profound	O
thrombocytopenia,	O
there	O
was	O
concern	O
for	O
spontaneous	O
pulmonary	O
hemorrhage	O
v.	O
PNA,	B-Lower_respiratory_tract_infection
and	O
CXR	O
was	O
notable	O
for	O
a	O
new	O
heterogeneous	O
opacification	O
confined	O
to	O
the	O
right	O
lower	O
lobe,	O
called	O
pneumonia,	B-Lower_respiratory_tract_infection
pulmonary	O
hemorrhage	O
or	O
both.	O
The	O
episodes	O
of	O
hemoptysis	O
did	O
not	O
compromise	O
his	O
respiratory	O
status,	O
and	O
he	O
was	O
breathing	O
comfortably	O
and	O
hemodynamically	O
stable.	O
He	O
was	O
treated	O
with	O
one	O
dose	O
of	O
PO	O
Amicar	O
in	O
the	O
setting	O
of	O
ongoing	O
hemoptysis,	O
after	O
consultation	O
with	O
hematology	O
and	O
cardiology.	O
A	O
TB	O
rule-out	O
was	O
also	O
initiated,	O
despite	O
low	O
suspicion	O
based	O
on	O
his	O
radiographic	O
findings	O
and	O
remote	O
exposure	O
(a	O
family	O
member	O
in	O
the	O
___	O
exposed	O
him	O
to	O
TB,	O
and	O
he	O
had	O
had	O
subsequent	O
negative	O
PPDs).	O
#	O
acute	O
coronary	O
syndrome:	O
On	O
___,	O
after	O
an	O
IVIG	O
infusion,	O
he	O
complained	O
of	O
shortness	O
of	O
breath,	O
and	O
an	O
EKG	O
was	O
demonstrated	O
dynamic	O
EKG	O
changes	O
(ST	O
elevation	O
1mm	O
V1-3,	O
ST	O
depressions	O
II/II,	O
AvF,	O
and	O
subsequently	O
V4-5).	O
He	O
subsequently	O
developed	O
chest	O
pressure,	O
and	O
ECHO	O
on	O
___	O
consistent	O
with	O
mid-LAD	O
lesion.	O
EKG	O
on	O
___epression	O
in	O
inferior	O
leads	O
and	O
subtle	O
ST	O
elevations	O
in	O
precordial	O
leads	O
(V1-V3).	O
His	O
chest	O
pain	O
resolved	O
with	O
nitropaste/morphine.	O
Enzymes	O
showed	O
uptrending	O
troponin	O
and	O
new	O
elevated	O
CKMB.	O
He	O
was	O
treated	O
with	O
atorvastatin	O
80,	O
spironolactone	O
25,	O
metoprolol	O
succinate	O
50.	O
Aspirin	O
was	O
held	O
given	O
thrombocytopenia.	O
Coronary	O
catheterization	O
was	O
deferred	O
until	O
platelets	O
stable	O
and	O
>50,	O
a	O
threshold	O
that	O
was	O
unfortunately	O
not	O
achieved,	O
and	O
platelet	O
transfusions	O
had	O
to	O
be	O
given	O
with	O
lasix	O
to	O
decrease	O
the	O
volume	O
load	O
of	O
infusion,	O
as	O
platelet	O
transfusions	O
were	O
temporally	O
associated	O
with	O
recurrence	O
of	O
chest	O
pain.	O
#	O
SOB:	O
He	O
initially	O
noted	O
dyspnea	O
in	O
the	O
setting	O
of	O
fluid	O
overload	O
after	O
getting	O
IVIG,	O
and	O
he	O
continued	O
to	O
feel	O
SOB	O
after	O
platelet	O
transfusions.	O
Underlying	O
COPD	O
may	O
have	O
contributed,	O
for	O
which	O
nebs	O
were	O
provided.	O
Chest	O
x-ray	O
on	O
___	O
without	O
evidence	O
of	O
pulmonary	O
edema,	O
but	O
some	O
concern	O
for	O
RLL	O
infiltrate;	O
repeat	O
CXR	O
on	O
___	O
raised	O
concern	O
for	O
PNA,	B-Lower_respiratory_tract_infection
and	O
he	O
was	O
treated	O
with	O
vancomycin/cefepime.	O
He	O
was	O
afebrile,	O
and	O
his	O
cough	O
was	O
productive	O
of	O
bloody	O
sputum	O
as	O
above.	O
There	O
was	O
also	O
likely	O
contribution	O
from	O
diastolic	O
CHF,	O
for	O
which	O
he	O
was	O
treated	O
with	O
torsemide	O
40	O
mg	O
on	O
___,	O
which	O
was	O
subsequently	O
held	O
given	O
increase	O
in	O
creatinine	O
and	O
euvolemia,	O
and	O
transitioned	O
to	O
PO	O
lasix	O
20	O
mg	O
daily,	O
starting	O
on	O
___.	O
Additionally,	O
he	O
was	O
treated	O
with	O
incentive	O
spirometry,	O
and	O
morphine	O
Sulfate	O
(Oral	O
Soln.)	O
2.5-5	O
mg	O
PO/NG	O
Q6H:PRN	O
chest	O
discomfort	O
per	O
palliative	O
care	O
recs.	O
#	O
HCV	O
Cirrhosis:	O
complicated	O
by	O
esophageal	O
varices	O
(no	O
hx	O
of	O
bleeding/banding),	O
no	O
HE,	O
no	O
ascites.	O
On	O
presentation,	O
his	O
HCV	O
viral	O
load	O
=	O
1,580,000.	O
Given	O
that	O
he	O
was	O
HBcAb+,	O
sAb	O
negative,	O
he	O
was	O
started	O
on	O
prophylaxis	O
for	O
HBV	O
reactivation	O
with	O
lamivudine	O
100mg	O
daily	O
in	O
the	O
setting	O
of	O
receiving	O
IVIG,	O
steroids,	O
and	O
rituximab	O
for	O
treatment	O
of	O
ITP.	O
He	O
was	O
planning	O
to	O
have	O
HCV	O
treatment	O
once	O
medically	O
stable	O
and	O
a	O
surveillance	O
EGD	O
once	O
his	O
platelets	O
stabilized.	O
#	O
Elevated	O
LFTs:	O
initial	O
elevation	O
with	O
AST:	O
ALT	O
ratio	O
2:1	O
consistent	O
with	O
history	O
of	O
alcohol	O
use.	O
Imaging	O
was	O
notable	O
for	O
bile	O
duct	O
strictures;	O
CA	O
___	O
level	O
was	O
subsequently	O
checked	O
and	O
was	O
elevated	O
at	O
282.	O
He	O
had	O
plans	O
for	O
repeat	O
MRI	O
(with	O
___	O
protocol)	O
and	O
MRCP	O
for	O
follow	O
up	O
as	O
an	O
outpatient	O
to	O
better	O
evaluate	O
bile	O
duct	O
strictures	O
in	O
3	O
months	O
per	O
GI.	O
#	O
Pancreatitis:	O
Resolved;	O
no	O
abdominal	O
pain,	O
tolerating	O
POs.	O
On	O
initial	O
presentation	O
had	O
N/V,	O
epigastric	O
tenderness,	O
WBC	O
8.3,	O
lipase	O
1100,	O
bili	O
6.1,	O
and	O
mild	O
transaminitis.	O
CT	O
at	O
that	O
time	O
showed	O
inflammation	O
and	O
stranding	O
in	O
pancreatic	O
head	O
and	O
duodenum.	O
Etiology	O
likely	O
due	O
to	O
alcohol.	O
Ddx	O
also	O
includes	O
gallstone	O
which	O
subsequently	O
passed.	O
#	O
Thrush:	O
Nystatin	O
swish	O
and	O
swallow	O
was	O
provided.	O
Chronic	O
issues:	O
#	O
HTN:	O
Continued	O
propranolol,	O
lisinopril.	O
#	O
Recent	O
AAA	O
repair:	O
Stable.	O
Continued	O
Simvastatin.	O
Code	O
status:	O
Full	O
code	O
Transitional	O
issues:	O
none;	O
patient	O
deceased	O
___	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
2.	O
Klor-Con	O
M20	O
(potassium	O
chloride)	O
20	O
mEq	O
oral	O
DAILY	O
3.	O
lisinopril-hydrochlorothiazide	O
___	O
mg	O
oral	O
DAILY	O
4.	O
Loratadine	O
10	O
mg	O
PO	O
DAILY:PRN	O
allergies	O
5.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
6.	O
Propranolol	O
LA	O
120	O
mg	O
PO	O
DAILY	O
7.	O
Simvastatin	O
20	O
mg	O
PO	O
DAILY	O
8.	O
Magnesium	O
Oxide	O
400	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
patient	O
deceased	O
Discharge	O
Disposition:	O
Expired	O
Discharge	O
Diagnosis:	O
patient	O
deceased	O
Discharge	O
Condition:	O
patient	O
deceased	O
Discharge	O
Instructions:	O
patient	O
deceased	O
Followup	O
Instructions:	O
___	O

